» Articles » PMID: 20938721

Comparison Between Clinical Significance of Serum Proinflammatory Proteins (IL-6 and CRP) and Classic Tumor Markers (CEA and CA 19-9) in Gastric Cancer

Overview
Journal Clin Exp Med
Specialty General Medicine
Date 2010 Oct 13
PMID 20938721
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric cancer (GC) is a second most common cause of cancer-related death and represents an inflammation-driven malignancy. It has been suggested that interleukin 6 (IL-6) and C-reactive protein (CRP) play a potential role in the growth and progression of GC. The aim of the present study was to compare clinical significance of IL-6 and CRP with classic tumor markers-carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) in GC patients. The study included 92 patients with GC and 70 healthy subjects. The serum concentrations of IL-6, CEA and CA 19-9 were determined using immunoenzyme assays, whereas CRP using immunoturbidimetric method. We defined the diagnostic criteria and prognostic value for proteins tested. In GC patients, the serum concentrations of all the proteins tested were significantly higher than in healthy subjects. The IL-6, CEA and CA 19-9 levels correlated with nodal metastases, while CRP with tumor stage, gastric wall invasion, presence of nodal and distant metastases. Diagnostic sensitivity of IL-6 was higher (85%) than those of other markers (CRP 66%, CA 19-9 34%, CEA 22%) and increased in combined use with CRP or CEA (88%). The area under ROC curve for IL-6 was larger than those of CRP and classic tumor markers (CEA and CA 19-9). None of the proteins tested was independent prognostic factor for the survival of GC patients. Our findings indicate better usefulness of serum proinflammatory proteins-IL-6 and CRP than classic tumor markers-CEA and CA 19-9 in the diagnosis of GC.

Citing Articles

C-reactive protein kinetics as a predictive marker for long-term outcome of immune checkpoint inhibitors in oesophagogastric cancer.

Nose Y, Saito T, Kurokawa Y, Takahashi T, Yamamoto K, Momose K BJC Rep. 2024; 1(1):7.

PMID: 39516365 PMC: 11524005. DOI: 10.1038/s44276-023-00005-x.


The future of metronomic chemotherapy: experimental and computational approaches of drug repurposing.

Abdelrady Y, Thabet H, Sayed A Pharmacol Rep. 2024; 77(1):1-20.

PMID: 39432183 DOI: 10.1007/s43440-024-00662-w.


Application of serum gastric function markers and digestive tumor indices to the diagnosis of early gastric cancer and precancerous lesions.

Yanan Z, Juan W, Jun W, Xin M, Kejian W, Fangyu W Saudi Med J. 2023; 44(8):795-800.

PMID: 37582570 PMC: 10425617. DOI: 10.15537/smj.2023.44.8.20230231.


The Comprehensive Analysis of Specific Proteins as Novel Biomarkers Involved in the Diagnosis and Progression of Gastric Cancer.

Pawluczuk E, Lukaszewicz-Zajac M, Mroczko B Int J Mol Sci. 2023; 24(10).

PMID: 37240178 PMC: 10218496. DOI: 10.3390/ijms24108833.


A Disintegrin and Metalloproteinase (ADAM) Family-Novel Biomarkers of Selected Gastrointestinal (GI) Malignancies?.

Lukaszewicz-Zajac M, Paczek S, Mroczko B Cancers (Basel). 2022; 14(9).

PMID: 35565436 PMC: 9101749. DOI: 10.3390/cancers14092307.


References
1.
Mroczko B, Wereszczynska-Siemiatkowska U, Groblewska M, Lukaszewicz M, Szmitkowski M, Gryko M . The diagnostic value of hematopoietic cytokines measurement in the sera of gastric cancer and gastric ulcer patients. Clin Chim Acta. 2006; 374(1-2):165-7. DOI: 10.1016/j.cca.2006.05.037. View

2.
Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T . Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer. 2005; 8(2):124-31. DOI: 10.1007/s10120-005-0315-x. View

3.
Ilhan N, Ilhan N, Ilhan Y, Akbulut H, Kucuksu M . C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol. 2004; 10(8):1115-20. PMC: 4656344. DOI: 10.3748/wjg.v10.i8.1115. View

4.
Kallio R, Surcel H, Bloigu A, Syrjala H . C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients. Eur J Cancer. 2000; 36(7):889-94. DOI: 10.1016/s0959-8049(00)00018-6. View

5.
Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto Y . Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res. 2007; 27(4C):3001-4. View